Vanderbilt Ingram Cancer Center

For more VICC news, visit their website »

November 18, 2021

Chic Awearness gala to support ovarian cancer research set for Dec. 6

Chic Awearness, a fashion show and fundraiser for ovarian cancer research, returns as an in-person event from 6:30 p.m. to 8:30 p.m. on Monday, Dec. 6.

By Tom Wilemon
November 4, 2021

Koerkenmeier named VICC associate nursing officer

By Tom Wilemon
November 2, 2021

Shifts in neuroendocrine cancer clinical trial design

Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.

By Leigh MacMillan
October 28, 2021

VICC’s Mayer departing to take new role with AstraZeneca

Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.

By Tom Wilemon
October 21, 2021

Study to evaluate how environment impacts cancer risk

Vanderbilt-Ingram Cancer Center is leading an ambitious project to assess the impact of environmental exposures on cancer risk for people living in Southern states.

By Tom Wilemon
Twenty-four hours after the administration of the study drug, catheters are inserted into the tumor and lasers emitting a wavelength of light that activates the dye molecule on the ASP-1929 are illuminated.
October 14, 2021

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.

By Tom Wilemon
September 30, 2021

Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription

Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.
By Tom Wilemon
September 23, 2021

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

By Doug Campbell
September 23, 2021

Eng named co-chair of NCI clinical trials steering committee

Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
By Tom Wilemon
September 16, 2021

Structural variants in breast cancer risk genes

Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.
By Leigh MacMillan
September 10, 2021

Novel immunotherapy shows robust response for multiple myeloma

Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
By Tom Wilemon
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
By Bill Snyder
August 19, 2021

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.
By Leigh MacMillan
1 … 8 9 10 11 12 … 55